Action TenX Keane Acquisition - TENK

Discussions et idées de trading en temps réel : négociez en toute confiance avec notre puissante plateforme.

Premium

Dernier

40,50

Prix Achat

40,50

Prix Vente

15,00

Volume échangé

0,00 Fourchette du Jour 0,00

0,00 Plage de 52 semaines 0,00

Cap du marché

269,45M

Clôture Veille

40,50

Ouverture

Dernière Transaction

Dernière heure de transaction

Volume financier

VWAP

Volume moyen (3 m)

Actions en circulation

6 653 077

Rendement du Dividende

Ratio Cours sur Bénéfices

-0,30

Bénéfice par action (BPA)

-3,18

Chiffre d'affairess

Bénéfice net

-21,15M

Secteur

Pharmaceutical Preparations

Industrie

Blank Checks

Site Web

www.citiusonc.com

Siège social

Dover, Delaware, USA

Fondé

2024

TenX Keane Acquisition Addresses Trading Halt, Continues Towards Closing of Business Combination, and Provides Market Update

TenX Keane shareholders voted to approve the previously announced merger with Citius Oncology at an...

TenX Keane Acquisition Shareholders Approve Previously Announced Merger to Form Citius Oncology, Inc., a Publicly Listed Subsidiary of Citius Pharmaceuticals

TenX Keane shareholders voted to approve the previously announced merger with Citius Oncology at an...

Citius Pharmaceuticals Details Near-Term Milestones for Late-Stage Candidates

Citius Pharmaceuticals Details Near-Term Milestones for Late-Stage Candidates PR Newswire CRANFORD, N.J., July...

TenX Keane Acquisition Announces Contribution to Trust Account in Connection with Extension Amendment Proposal

New York, NY, Jan. 10, 2024 (GLOBE NEWSWIRE) -- TenX Keane Acquisition (Nasdaq: TENKU, TENK, TENKR) (the...

Citius Pharmaceuticals Executes Definitive Agreement to Merge Wholly Owned Subsidiary with TenX Keane Acquisition to Form Publicly Listed Citius Oncology, Inc.

Citius Pharmaceuticals, Inc. to receive $675 million in equity of Citius Oncology, Inc. and retain...

TenX Keane Acquisition Announces Extension of the Deadline for an Initial Business Combination

New York, NY, Oct. 18, 2023 (GLOBE NEWSWIRE) -- TenX Keane Acquisition (the “Company”) (NASDAQ: TENKU) today...

TenX Keane Acquisition Announces Extension of the Deadline for an Initial Business Combination

New York, NY, July 18, 2023 (GLOBE NEWSWIRE) -- TenX Keane Acquisition (the “Company”) (NASDAQ: TENKU) today...

TenX Keane Acquisition Announces the Separate Trading of its Ordinary Shares and Rights Commencing on December 8, 2022

New York, NY, Dec. 06, 2022 (GLOBE NEWSWIRE) -- TenX Keane Acquisition (the “Company”) (Nasdaq: TENKU), a...

TenX Keane Acquisition Announces Closing of $66 Million Initial Public Offering, Including Partial Exercise of Underwriter’s Over-Allotment Option

New York, Oct. 18, 2022 (GLOBE NEWSWIRE) -- TenX Keane Acquisition (NASDAQ:TENKU) (the “Company”), a newly...

Période	Variation	Variation %	Ouver.	Haut	Bas	Moyenne Vol. Quot.	VWAP
1	0	0	0	0	0	0	0	CS
4	0	0	0	0	0	0	0	CS
12	0	0	0	0	0	0	0	CS
26	0	0	0	0	0	0	0	CS
52	0	0	0	0	0	0	0	CS
156	0	0	0	0	0	0	0	CS
260	0	0	0	0	0	0	0	CS

TENK - Frequently Asked Questions (FAQ)

What is the current TenX Keane Acquisition share price?

The current share price of TenX Keane Acquisition is US$ 40,50

How many TenX Keane Acquisition shares are in issue?

TenX Keane Acquisition has 6 653 077 shares in issue

What is the market cap of TenX Keane Acquisition?

The market capitalisation of TenX Keane Acquisition is USD 269,45M

What is the 1 year trading range for TenX Keane Acquisition share price?

TenX Keane Acquisition has traded in the range of US$ 0,00 to US$ 0,00 during the past year

What is the PE ratio of TenX Keane Acquisition?

The price to earnings ratio of TenX Keane Acquisition is -0,3

What is the reporting currency for TenX Keane Acquisition?

TenX Keane Acquisition reports financial results in USD

What is the latest annual profit for TenX Keane Acquisition?

The latest annual profit of TenX Keane Acquisition is USD -21,15M

What is the registered address of TenX Keane Acquisition?

The registered address for TenX Keane Acquisition is 3500 SOUTH DUPONT HIGHWAY, DOVER, DELAWARE, 19901

What is the TenX Keane Acquisition website address?

The website address for TenX Keane Acquisition is www.citiusonc.com

Which industry sector does TenX Keane Acquisition operate in?

TenX Keane Acquisition operates in the BLANK CHECKS sector

Volume
% Gagnants
% Perdants

Symbole	Prix	Vol.
CAPSCapstone Holding Corp	US$ 3,50 (1 300,00%)	36,33k
ABLVAble View Global Inc	US$ 1,73 (137,18%)	5,13M
SUNESUNation Energy Inc	US$ 0,402999 (127,55%)	476,73M
BTOGBit Origin Ltd	US$ 0,6117 (118,46%)	618,03M
DWTXDogwood Therapeutics Inc	US$ 6,63 (49,66%)	25,77M
ALBTAvalon GloboCare Corporation	US$ 6,96 (-36,15%)	570,43k
SCNXScienture Holdings Inc	US$ 1,55 (-35,68%)	1,54M
ACXPAcurx Pharmaceuticals Inc	US$ 0,4572 (-29,88%)	1,13M
RETOReTo Eco Solutions Inc	US$ 5,42 (-27,73%)	108k
OCTOEightco Holdings Inc	US$ 1,08 (-27,03%)	332,1k
BTOGBit Origin Ltd	US$ 0,6117 (118,46%)	622,67M
SUNESUNation Energy Inc	US$ 0,402999 (127,55%)	482,05M
NVDANVIDIA Corporation	US$ 112,69 (1,92%)	341,94M
TSLLDirexion Daily TSLA Bull 2X Trust ETF	US$ 10,675 (-0,70%)	143,04M
ICONIcon Energy Corporation	US$ 0,169898 (17,17%)	142,23M

Forums

Afficher les forums

Aucune Discussion Trouvée

Ajouter une Discussion

Donnée du Marché

Actualité

Outils

Donnée du Marché

Discover

Hot Features

Follow Feed

Flux des Options

Moniteur

TenX Keane Acquisition (TENK)

Discussions et idées de trading en temps réel : négociez en toute confiance avec notre puissante plateforme.

Statistiques et détails clés

À propos de TenX Keane Acquisition

TENK Dernières nouvelles

TenX Keane Acquisition Addresses Trading Halt, Continues Towards Closing of Business Combination, and Provides Market Update

TenX Keane Acquisition Shareholders Approve Previously Announced Merger to Form Citius Oncology, Inc., a Publicly Listed Subsidiary of Citius Pharmaceuticals

Citius Pharmaceuticals Details Near-Term Milestones for Late-Stage Candidates

TenX Keane Acquisition Announces Contribution to Trust Account in Connection with Extension Amendment Proposal

Citius Pharmaceuticals Executes Definitive Agreement to Merge Wholly Owned Subsidiary with TenX Keane Acquisition to Form Publicly Listed Citius Oncology, Inc.

TenX Keane Acquisition Announces Extension of the Deadline for an Initial Business Combination

TenX Keane Acquisition Announces Extension of the Deadline for an Initial Business Combination

TenX Keane Acquisition Announces the Separate Trading of its Ordinary Shares and Rights Commencing on December 8, 2022

TenX Keane Acquisition Announces Closing of $66 Million Initial Public Offering, Including Partial Exercise of Underwriter’s Over-Allotment Option

TenX Keane Acquisition Addresses Trading Halt, Continues Towards Closing of Business Combination, and Provides Market Update

TenX Keane Acquisition Shareholders Approve Previously Announced Merger to Form Citius Oncology, Inc., a Publicly Listed Subsidiary of Citius Pharmaceuticals

Citius Pharmaceuticals Details Near-Term Milestones for Late-Stage Candidates

TENK - Frequently Asked Questions (FAQ)

Moteurs

Forums

Dernières Valeurs Consultées

Société

Entreprise

Popular

Obtenir l'application

Période	Variation	Variation %	Ouver.	Haut	Bas	Moyenne Vol. Quot.	VWAP
1	0	0	0	0	0	0	0	CS
4	0	0	0	0	0	0	0	CS
12	0	0	0	0	0	0	0	CS
26	0	0	0	0	0	0	0	CS
52	0	0	0	0	0	0	0	CS
156	0	0	0	0	0	0	0	CS
260	0	0	0	0	0	0	0	CS

Période	Variation	Variation %	Ouver.	Haut	Bas	Moyenne Vol. Quot.	VWAP
1	0	0	0	0	0	0	0	CS
4	0	0	0	0	0	0	0	CS
12	0	0	0	0	0	0	0	CS
26	0	0	0	0	0	0	0	CS
52	0	0	0	0	0	0	0	CS
156	0	0	0	0	0	0	0	CS
260	0	0	0	0	0	0	0	CS

Donnée du Marché

Actualité

Outils

Donnée du Marché

Discover

Hot Features

Follow Feed

Flux des Options

Moniteur

TenX Keane Acquisition (TENK) Cours

TenX Keane Acquisition (TENK)

Discussions et idées de trading en temps réel : négociez en toute confiance avec notre puissante plateforme.

Statistiques et détails clés

À propos de TenX Keane Acquisition

TENK Dernières nouvelles

TenX Keane Acquisition Addresses Trading Halt, Continues Towards Closing of Business Combination, and Provides Market Update

TenX Keane Acquisition Shareholders Approve Previously Announced Merger to Form Citius Oncology, Inc., a Publicly Listed Subsidiary of Citius Pharmaceuticals

Citius Pharmaceuticals Details Near-Term Milestones for Late-Stage Candidates

TenX Keane Acquisition Announces Contribution to Trust Account in Connection with Extension Amendment Proposal

Citius Pharmaceuticals Executes Definitive Agreement to Merge Wholly Owned Subsidiary with TenX Keane Acquisition to Form Publicly Listed Citius Oncology, Inc.

TenX Keane Acquisition Announces Extension of the Deadline for an Initial Business Combination

TenX Keane Acquisition Announces Extension of the Deadline for an Initial Business Combination

TenX Keane Acquisition Announces the Separate Trading of its Ordinary Shares and Rights Commencing on December 8, 2022

TenX Keane Acquisition Announces Closing of $66 Million Initial Public Offering, Including Partial Exercise of Underwriter’s Over-Allotment Option

TenX Keane Acquisition Addresses Trading Halt, Continues Towards Closing of Business Combination, and Provides Market Update

TenX Keane Acquisition Shareholders Approve Previously Announced Merger to Form Citius Oncology, Inc., a Publicly Listed Subsidiary of Citius Pharmaceuticals

Citius Pharmaceuticals Details Near-Term Milestones for Late-Stage Candidates

TENK - Frequently Asked Questions (FAQ)

Moteurs

Forums

Dernières Valeurs Consultées

Société

Entreprise

Popular

Obtenir l'application

Supprimer les publicités

Période	Variation	Variation %	Ouver.	Haut	Bas	Moyenne Vol. Quot.	VWAP
1	0	0	0	0	0	0	0	CS
4	0	0	0	0	0	0	0	CS
12	0	0	0	0	0	0	0	CS
26	0	0	0	0	0	0	0	CS
52	0	0	0	0	0	0	0	CS
156	0	0	0	0	0	0	0	CS
260	0	0	0	0	0	0	0	CS